MedPath

ChiRhoClin, Inc.

ChiRhoClin, Inc. logo
🇺🇸United States
Ownership
Private
Established
1991-01-01
Employees
1
Market Cap
-
Website
http://www.chirhoclin.com

Clinical Trials

3

Active:0
Completed:2

Trial Phases

3 Phases

Phase 1:1
Phase 2:1
Phase 3:1

Drug Approvals

1

FDA:1

Drug Approvals

ChiRhoStim

Approval Date
Oct 14, 2021
FDA

Clinical Trials

Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials

Phase 1
1 (33.3%)
Phase 2
1 (33.3%)
Phase 3
1 (33.3%)

Secretin for Acute Pancreatitis

Phase 2
Conditions
Pancreatitis, Acute
Interventions
First Posted Date
2018-09-27
Last Posted Date
2019-04-10
Lead Sponsor
ChiRhoClin, Inc.
Target Recruit Count
40
Registration Number
NCT03686618
Locations
🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

Secretin Infusion for Pain Due to Chronic Pancreatitis

Phase 1
Completed
Conditions
Chronic Pancreatitis
Interventions
First Posted Date
2010-12-23
Last Posted Date
2016-03-09
Lead Sponsor
ChiRhoClin, Inc.
Target Recruit Count
12
Registration Number
NCT01265875
Locations
🇺🇸

Dartmouth Hitchcock Medical Center, Lebanon, New Hampshire, United States

A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers

Phase 3
Completed
Conditions
Pancreatic Disease
Interventions
Drug: Placebo
First Posted Date
2010-03-16
Last Posted Date
2011-12-06
Lead Sponsor
ChiRhoClin, Inc.
Target Recruit Count
64
Registration Number
NCT01087801
Locations
🇺🇸

Saint Louis University, Saint Louis, Missouri, United States

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.